(MedPage Today) — A novel treatment based on CRISPR gene editing showed benefits in hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) in an early study.
Among 36 patients who received a one-time dose of investigational nexiguran…
Source link : https://www.medpagetoday.com/neurology/generalneurology/117732
Author :
Publish date : 2025-10-01 15:23:00
Copyright for syndicated content belongs to the linked Source.
